Scientific Program - Retina

Please see below the COPHy Scientific Program. Please click on the appropriate section to view the relevant program. Please note that the program is subject to change. To view the program timetable / overview, please click here

Anterior Segment Glaucoma Other
The future of world ophthalmology
Neil Bressler, USA
Anat Loewenstein, Israel
Jerzy Nawrocki, Poland
Ambassador Jerzy Koźmiński, Poland
OPENING SESSION | Poliferative diabetic retinopathy
Chairs: Neil Bressler, USA and Michael Larsen, Denmark
08:45-09:15 Proliferative diabetic retinopathy with diabetic macular edema
08:45-08:55 PRP for PDR & anti-VEGF for DME: Alfredo Pece, Italy
08:55-09:05 Why add PRP if using anti-VEGF for DME: Sobha Sivaprasad, UK
09:05-09:15 Discussion
09:15-09:45 Proliferative diabetic retinopathy without diabetic macular edema
09:15-09:25 PRP: Michael Larsen, Denmark
09:25-09:35 Anti-VEGF: Sobha Sivaprasad, UK
09:35-09:45 Discussion
09:45-10:15 Vitreous hemorrhage precluding PRP
09:45-09:55 Vitrectomy: Joseph Moisseiev, Israel
09:55-10:05 Anti-VEGF with deferral of vitrectomy: Bora Eldem, Turkey
10:05-10:15 Discussion
10:15-10:45 Visit to Exhibition & Coffee and Refreshment Break
RETINA I | Non-neovascular ("Dry”) Age-related Macular Degeneration
Chairs: Bozena Romanowska-Dixon, Poland, and Eric Souied, France
10:45-11:15 Genetic Testing will be part of standard care in AMD
10:45-10:55 Yes: Eric Souied, France
10:55-11:05 No: William F. Mieler, USA
11:05-11:15 Discussion
11:15-11:45 Lampalizumab: Phase 2 study warrants phase 3 studies
11:15-11:25 Yes: Faruque Ghanchi, UK
11:25-11:35 No: Anat Loewenstein, Israel
11:35-11:45 Discussion
11:45-12:15 Monitoring for CNV development
11:45-11:55 Home devices: Susan Bressler, USA
11:55-12:05 Quarterly office evaluation: Faruque Ghanchi, UK
12:05-12:15 Discussion
12:15-12:45 Visit to Exhibition & Lunch Box Pick-up
13:45-14:15 Visit to Exhibition & Dessert Break
RETINA II | Surgical
Chairs: Francesco Boscia, Italy, Joseph Moisseiev, Israel and William F. Mieler, USA
14:15-14:45 Giant tear
14:15-14:25 All you need is gas: Francesco Boscia, Italy
14:25-14:35 Silicone oil is the first choice: Zofia Michalewska, Poland
14:35-14:45 Discussion
14:45-15:15 Intraoperative OCT
14:45-14:55 An expensive toy: Marc D de Smet, Switzerland
14:55-15:05 A valuable addition to vitrectomy: Stanislao Rizzo, Italy
15:05-15:15 Discussion
15:15-15:45 Surgical panel case discussion
Moderators: William Mieler, USA and Joseph Moisseiev, Israel
Panel: Francesco Boscia, Italy, Zofia Michalewska, Poland, Stanislao Rizzo, Italy, Marta Figueroa, Spain
15:45-16:00 Visit to Exhibition & Coffee and Refreshment Break

Controversies in geographic atrophy of the RPE:
no longer a "dry” topic
Chairs: Neil Bressler, USA, Francesco Bandello, Italy, Anat Loewenstein, Israel and Sobha Sivaprasad, UK
Breakfast will be provided
07:30-07:36 Introduction and Goals of Symposium: Sobha Sivaprasad, UK
07:36-07:45 What's the best way to image geographic atrophy? Giovanni Staurenghi, Italy
07:45-07:50 Questions
07:50-07:58 Is there a role for dietary supplements for geographic atrophy? Susan Bressler, USA
07:58-08:02 Questions
08:02-08:10 Genetic issues relevant to geographic atrophy? (Pattern dystrophies, complement factor inhibitors) Hendrik Scholl, USA
08:10-08:14 Questions
08:14-08:22 Is there a rationale to pursue a Phase 3 trial of lampalizumab based on Mahalo? Faruque Ghanchi, UK
08:22-08:26 Questions
08:26-08:30 Conclusions and next steps: Neil Bressler, USA
RETINA III | Diabetic Macular Edema
Chairs: José Cunha-Vaz, Portugal and Susan Bressler, USA
09:00-09:30 Fluorescein angiography in management of DME
09:00-09:10 Generally not required to manage DME: Zofia Michalewska, Poland
09:10-09:20 Generally required to manage DME: Sobha Sivaprasad, UK
09:20-09:30 Discussion
09:30-10:00 Add Focal/Grid Laser if DME Persists Despite Anti-VEGF
09:30-09:40 Yes: José Cunha-Vaz, Portugal
09:40-09:50 No: Patricia Udaondo, Spain
09:50-10:00 Discussion
10:00-10:30 First agent to choose for mild center-involved DME (<450 microns) with mild visual acuity loss (20/40 or better)?
10:00-10:10 Bevacizumab: Sobha Sivaprasad, UK
10:10-10:20 Aflibercept or ranibizumab: Ian Pearce, UK
10:20-10:30 Discussion
10:30-10:45 Visit to Exhibition & Coffee and Refreshment Break
RETINA IV | Surgical
Chairs: Marta Figueroa, Spain, Joseph Moisseiev, Israel, Jerzy Nawrocki, Poland and Stanislao Rizzo, Italy
10:45-11:15 PPV with concurrent cataract extraction
10:45-10:55 Concurrently: William Mieler, USA
10:55-11:05 Sequentially: Francesco Boscia, Italy
11:05-11:15 Discussion
11:15-11:45 27G today
11:15-11:25 Smaller is better: Stanislao Rizzo, Italy
11:25-11:35 A technology looking for uses: William Mieler, USA
11:35-11:45 Discussion
11:45-12:15 RD with inferior breaks in Phakic eyes
11:45-11:53 Buckle: Joseph Moisseiev, Israel
11:53-12:01 Vitrectomy: Jerzy Nawrocki, Poland
12:01-12:09 Novel techniques: Teresio Avitabile, Italy
12:09-12:15 Discussion
12:15-12:45 Visit to Exhibition & Lunch Box Pick-up
RETINA V | Neovascular ("Wet”) AMD Management
Chairs: Francesco Bandello, Italy, Faruque Ghanchi, UK and Alfredo Pece, Italy
14:15-14:45 Which agent first?
14:15-14:23 Bevacizumab – cost-effectiveness cannot be surpassed: Barry Kuppermann, USA
14:23-14:31 Rationale for ranibizumab: Francesco Bandello, Italy
14:31-14:39 Rationale for aflibercept: Faruque Ghanchi, UK
14:39-14:45 Discussion
14:45-15:15 Preferred visit regimen for first 2 years of anti-VEGF therapy
14:45-14:55 Treat and extend: Patricia Udaondo, Spain
14:55-15:05 Monthly monitoring with PRN ranibizumab or monthly aflibercept (x5) then q8 week: Ian Pearce, UK
15:05-15:15 Discussion
15:15-15:45 Intravitreous injections should include antibiotics drops to reduce endophthalmitis rate
15:15-15:25 Yes: Anna Machalinska, Poland
15:25-15:35 No: Andrzej Grzybowski, Poland
15:35-15:45 Discussion
15:45-16:00 Visit to Exhibition & Coffee and Refreshment Break
Chairpersons: Paolo Lanzetta, Italy; Zofia Michalewska, Poland
16:00-16:30 Macular edema from retinal vein occlusion – no improvement after 3 injections – what to do next?
16:00-16:10 Continue anti-VEGF: Susan Bressler, USA
16:10-16:20 Switch to corticosteroids: Bora Eldem, Turkey
16:20-16:30 Discussion
16:30-17:00 Macular edema from retinal vein occlusion: which agent?
16:30-16:40 Aflibercept: Ian Pearce, UK
16:40-16:50 Ranibizumab: Paolo Lanzetta, Italy
16:50-17:00 Discussion
17:00-17:30 CRVO and Iris/Angle neovascularization
17:00-17:10 Anti-VEGF alone: José Cunha-Vaz, Portugal
17:10-17:20 Anti-VEGF plus PRP: Andrzej Grzybowski, Poland
17:20-17:30 Discussion